Maze Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $20MTTM through 30 Jun 2026
Net Income -$133.6M-355.8% YoYTTM through 30 Jun 2026
Free Cash Flow -$106.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -714.3% |
| Operating Margin | -132.8% |
| Net Margin | -121.0% |
Returns
-38.7%ROE
-22.3%ROA
Balance Sheet Health
Debt / Equity0.18x
Current Ratio18.31x
Net Debt-$301.7Mnet cash position
Cash & Equivalents$202.6M
Quality Metrics
Altman Z-Score10.61
Piotroski F-Score3 / 9
FCF Margin-534.2%
Rule of 40-534.2
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2024: $167.5M
Diluted EPS-$2.44TTMFY2025: $-3.05
Dividend
No dividend
Capital Allocation
Capex Intensity1.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Drug Discovery and Development | $20M | View detailsAdvancing MZE829 into a pivotal program in moderate AMKD without diabetes in 1H 2027, and initiating Phase 2 trials for MZE782. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.